Skip to main content
Open Access Publications from the University of California

Intravenous gadoxetate disodium administration reduces breath-holding capacity in the hepatic arterial phase: A multi-center randomized placebo-controlled trial

  • Author(s): McClellan, TR
  • Motosugi, U
  • Middleton, MS
  • Allen, BC
  • Jaffe, TA
  • Miller, CM
  • Reeder, SB
  • Sirlin, CB
  • Bashir, MR
  • et al.

Published Web Location
No data is associated with this publication.

© 2016 RSNA. Purpose: To determine, in a multicenter double-blinded placebocontrolled trial, whether maximal hepatic arterial phase breath-holding duration is affected by gadoxetate disodium administration. Materials and Methods: Institutional review board approval was obtained for this prospective multi-institutional HIPAA-compliant study; written informed consent was obtained from all subjects. At three sites, a total of 44 volunteers underwent a magnetic resonance (MR) imaging examination in which images were acquired before and dynamically after bolus injection of gadoxetate disodium, normal saline, and gadoterate meglumine, administered in random order in a single session. The technologist and volunteer were blinded to the agent. Arterial phase breath-holding duration was timed after each injection, and volunteers reported subjective symptoms. Heart rate (HR) and oxygen saturation were monitored. Images were independently analyzed for motion artifacts by three radiologists. Arterial phase breathholding duration and motion artifacts after each agent were compared by using the Mann-Whitney U test and the McNemar test. Factors affecting the above outcomes were assessed by using a univariate, multivariable model. Results: Arterial phase breath holds were shorter after gadoxetate disodium (mean, 32 seconds ± 19) than after saline (mean, 40 seconds ± 17; P <.001) or gadoterate meglumine (43 seconds ± 21, P <.001) administration. In 80% (35 of 44) of subjects, arterial phase breath holds were shorter after gadoxetate disodium than after both saline and gadoterate meglumine. Three (7%) of 44 volunteers had severe arterial phase motion artifacts after gadoxetate disodium administration, one (2%; P =.62) had them after gadoterate meglumine administration, and none (P =.25) had them after saline administration. HR and oxygen saturation changes were not signifcantly associated with contrast agent. Conclusion: Maximal hepatic arterial phase breath-holding duration is reduced after gadoxetate disodium administration in healthy volunteers, and reduced breath-holding duration is associated with motion artifacts.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item